teriparatide treatment
Recently Published Documents


TOTAL DOCUMENTS

172
(FIVE YEARS 49)

H-INDEX

25
(FIVE YEARS 3)

2022 ◽  
Vol 12 (5) ◽  
pp. 958-963
Author(s):  
Fei Gao ◽  
Xiaoming Wu ◽  
Zhao Guo ◽  
Jianzhong Wang ◽  
Wenshan Gao ◽  
...  

This study explored whether teriparatide promotes BMSCs proliferation and differentiation via downregulating miR-298 and provided a basis for bone repair. Based on the microarray analysis after teriparatide treatment, qRT-PCR verified the differentially expressed miRNAs and the osteogenic differentiation was assessed by transfection of miRNA overexpression plasmids and miRNA inhibitors. miRNA array analysis and qRT-PCR verification showed that miR-298 was significantly downregulated during teriparatide-induced BMSCs differentiation. miR-298 overexpression significantly inhibited ALP and OPN expression which was promoted by transfection of miR-298 inhibitor. miR-298 is a negative regulator of BMSCs differentiation induced by teriparatide. Dlx5 is the target of miR-298. Inhibition of DLX5 expression by miR-298 was involved in the osteogenic differentiation of BMSCs. In conclusion, miR-298 negatively regulates the differentiation of BMSCs induced by teriparatide by targeting DLX5, providing a possible therapeutic target for bone tissue repair and regeneration.


2021 ◽  
Author(s):  
Pun Yuet Lam ◽  
Prudence Wing Hang Cheung ◽  
Sin Ting Lau ◽  
Jason Pui Yin Cheung

Abstract Background: To evaluate and compare the effects of parathyroid hormone analogues, receptor activator of nuclear factor kappa-B ligand inhibitors (RANKL inhibitors) and bisphosphonates on the quality of life of postmenopausal women.Methods: A prospective observational study of 23 matched post-menopausal women was conducted with propensity score analysis on quality of life (QOL). Baseline and 12-month follow-up data were compared. Visual analogue scale (VAS) for back pain, the Osteoporosis Assessment Questionnaire-Physical Function (OPAQ-PF), EuroQol 5-level 5-dimension (EQ-5D-5L) questionnaire, ambulatory status assessment and Adherence Evaluation of Osteoporosis treatment (ADEOS-12) were carried out as QOL or treatment adherence measurements. A general linear model with inverse probability of treatment weighting (IPTW) adjustment with propensity score was constructed to predict one-year average back pain progression.Results: Teriparatide use was associated with significant improvements in VAS back pain (most severe pain reduced from 8.0 to 0.0, p=0.029; average pain reduced from 6.0 to 0.0, p=0.006), EQ-5D-5L general health status (EQ-5D summary index scores increased from 0.47 to 0.87, p=0.001; EQ-VAS increased from 65.0 to 80.0, p=0.008) and OPAQ physical function (from 40.0 to 79.5, p<0.001), whereas denosumab and alendronate groups only demonstrated improved OPAQ scores but worsened back pain. Baseline average VAS back pain was the only significant factor predicting one-year average back pain progression (partial eta squared=0.617, p=0.001).Conclusions: One-year continuous teriparatide treatment is most effective in improving QOL outcomes in postmenopausal osteoporotic women, but baseline average VAS back pain remained the only predictive factor for one-year back pain progression in the IPTW adjusted model.


2021 ◽  
Vol 12 ◽  
Author(s):  
Yasuaki Hirooka ◽  
Yuji Nozaki ◽  
Saki Okuda ◽  
Masafumi Sugiyama ◽  
Koji Kinoshita ◽  
...  

ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantage of teriparatide obtained in the first 2 years would be maintained after the switch to denosumab.Materials and MethodsWe switched patients who had completed 24-month daily teriparatide treatment to denosumab (switch group, n=18) and compared their BMD every 6 months up to 48 months with the group who continued to receive denosumab (denosumab group, n=16).ResultsAt 48 months, the lumbar spine BMD was significantly increased from baseline in both groups (denosumab: 10.4 ± 8.7%, p&lt;0.001; switch: 14.2 ± 6.8%, p&lt;0.001). However, a significant increase in femoral neck BMD from baseline occurred only in the switch group (11.2 ± 14.6%, p&lt;0.05); denosumab (4.1 ± 10.8%). The total hip BMD increased significantly from baseline in both groups (denosumab: 4.60 ± 7.4%, p&lt;0.05; switch: 7.2 ± 6.9%, p&lt;0.01). Femoral neck BMD was significantly increased in the switch versus the denosumab group (p&lt;0.05).ConclusionIn GIO patients with prior bisphosphonate treatment, the advantage of teriparatide may be maintained after the treatment period. A continuous increase in BMD can be expected with teriparatide followed by denosumab.


Author(s):  
Chung-Hwan Chen ◽  
Abdulaziz H. Elsalmawy ◽  
Sophia Ish-Shalom ◽  
Seung-Jae Lim ◽  
Nadia S. AlAli ◽  
...  

AbstractThe Asian and Latin America Fracture Observational Study (ALAFOS) is a prospective, observational, single-arm study conducted in 20 countries across Asia, Latin America and the Middle East. ALAFOS evaluated new clinical vertebral and non-vertebral fragility fractures in relation to time on teriparatide, in postmenopausal women with osteoporosis in real-life clinical practice. Clinical fragility fractures, back pain, and health-related quality of life (HRQoL) were recorded in 6-month intervals for ≤ 24 months during teriparatide treatment and up to 12-months post-treatment. Data were analysed with piecewise exponential regression with inverse probability weighting for time to event outcomes and mixed-model repeated measures for back pain and HRQoL. 3054 postmenopausal women started teriparatide and attended ≥ one follow-up visit (mean [SD] age 72.5 [10.4] years). The median (95% CI) time to treatment discontinuation was 22.0 months (21.2, 22.8). During the treatment period, 111 patients (3.6%) sustained 126 clinical fractures (2.98 fractures/100 patient-years). Rates of new clinical fragility fractures were significantly decreased during the > 6–12, > 12–18, and > 18–24-month periods, as compared with the first 6 months of treatment (hazard ratio [HR] 0.57; 95% CI 0.37, 0.88; p = 0.012; HR 0.35; 95% CI 0.19, 0.62; p < 0.001; HR 0.43; 95% CI 0.23, 0.83; p = 0.011; respectively). Patients also reported an improvement in back pain and HRQoL (p < 0.001). These results provide data on the real-world effectiveness of teriparatide in the ALAFOS regions and are consistent with other studies showing reduction of fractures after 6 months of teriparatide treatment. These results should be interpreted in the context of the noncontrolled design of this observational study.


2021 ◽  
Vol 22 ◽  
Author(s):  
Miguel Saraiva ◽  
Ana Catarina Chaves ◽  
Guilherme Assunção ◽  
Joana Saraiva ◽  
Rui Carvalho

Author(s):  
Kalliopi Lampropoulou-Adamidou ◽  
Georgios Trovas ◽  
Ioannis K. Triantafyllopoulos ◽  
Maria P. Yavropoulou ◽  
Athanasios D. Anastasilakis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document